SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Owing to their fat-burning effects, SGLT2 inhibitors reduce the stored lipid droplets in steatotic hepatocytes and normalize liver tissue composition in patients with NAFLD, which in turn prevents subsequent disorders.